Patent Expiry

Patent/Exclusivity Expiry: ESOMEPRAZOLE MAGNESIUM

Other upcoming events for NRIX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: ESOMEPRAZOLE MAGNESIUM — NRIX Patent Expiry | BioSniper